Genetically Predicted Glucose-Dependent Insulinotropic Polypeptide (GIP) Levels and Cardiovascular Disease Risk Are Driven by Distinct Causal Variants in the <i>GIPR</i> Region.

"Duality of Interest. N.B. has recently changed positions and is now an employee of GlaxoSmithKline. P.B. and M.P.C. are employees and shareholders of Eli Lilly & Company. F.R. and F.G. receive grant funding from Eli Lilly & Company. F.R. and F.G. receive grant funding from AstraZeneca and F.G. is a consultant for Kallyope. No other potential conflicts of interest relevant to this article were reported."

"Funding. The EPIC-Norfolk study (https://doi.org/10.22025/2019.10.105.00004) has received funding from the Medical Research Council (MRC) (MR/N003284/1 and MC_UU_12015/1) and Cancer Research UK (C864/A14136). The genetics work in the EPIC-Norfolk study was funded by the MRC (MC_PC_13048). The Fenland study (10.22025/2017.10.101.00001) is funded by the MRC (MC_UU_12015/1). The authors further acknowledge support for genomics and metabolomics from the MRC (MC_PC_13046). F.G. and F.R. acknowledge funding by Wellcome (106262/Z/14/Z and 106263/Z/14/Z) and MRC (MRC_MC_UU_12012/3). N.J.W. is a National Institute for Health Research Senior Investigator."